Dynavax Initiates Pivotal Phase 3 Trial For HEPLISAV(TM), Hepatitis B Vaccine

Thu, 21 Dec 2006 02:00 PM EST

... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of a pivotal Phase 3 clinical trial of HEPLISAV, its hepatitis B virus (HBV) vaccine in Canada. Sites in the United States and in Europe are scheduled to participate in the study and are expected to begin dosing patients in early 2007. [click link for full article] ...